A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Clinical trial NCT05468697 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05468697
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-10
- Primary completion
- 2026-09-22
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.